News
-
-
-
COMMUNIQUÉ DE PRESSE
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
Simcere Pharmaceutical partners with Stanford Medicine to develop new therapies for Idiopathic Pulmonary Fibrosis, aiming to address unmet clinical needs. Collaboration will advance novel molecule research led by renowned experts -
-
-
COMMUNIQUÉ DE PRESSE
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment for inflammatory bowel disease. SIM0709, a novel bispecific antibody, aims to improve outcomes for patients worldwide
